App-Quantinova.ai

PET/CT and regional brain metabolic changes associated with depression in metastatic breast cancer.

Chandler H. Park - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Clinical benefits and risks associated with darbepoetin alfa and epoetin alfa treatment in patients with lung cancer and chemotherapy-induced anemia.

Angelica Tiotiu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Darbepoetin alfa

Percutaneous transhepatic biliary drainage in hepatopancreaticobiliary cancer: Contemporary efficacy.

Ravi Murthy - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

A clinical study on activity of NAMPT and SIRT1 gene expression in neutropenia with cancer chemotherapy.

Yukari Tsubata - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The associated factors of skeletal related events in patients with non-small cell lung cancer.

Toshiyuki Kozuki - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Safety of histamine H2 blocker concomitant administration in patients treated with high dose methotrexate regimen.

Yun Jung Choi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Methotrexate

Impact of oncologists attitudes toward end-of-life care on Patients access to palliative care.

Eduardo Bruera - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Predictive impact of quality of life measurements in chemotherapy treated advanced pancreatic cancer patients at a single Canadian cancer institution.

Christina Kim - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Epimorph

Incidence and risk of pneumonitis associated with nivolumab and pembrolizumab in patients with cancer: A meta-analysis of clinical trials.

Ling Peng - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pembrolizumab

A prospective, real-world study of treatment patterns in early-stage breast cancer (ESBC) patients (pts) at high risk for febrile neutropenia (FN).

Spyridon Tzivelekis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Solid malignancies

N/A

Factors correlating with shorter survival after treatment: Aiding oncologists to choose who (not) to receive palliative systemic therapy.

Patty PY Ho - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Spirituality, symptom distress and quality of life of Latin American patients with advanced cancer (LAAdCa): A multicenter study.

Marvin Omar Delgado-Guay - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Solid malignancies

N/A

The impact of an educational program on patient practices on safe use, storage, and disposal of opioids in a comprehensive cancer center.

Maxine Grace De la Cruz - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Epimorph

Prevalence, risk factors, and sequelae of long-term chemotherapy-induced peripheral neuropathy (CIPN) among breast cancer survivors.

Ting Bao - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

taxane

Multicenter case registry study on medication-related osteonecrosis of the jaw in advanced cancer patients.

Morten Schiodt - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Should ASCO re-examine the febrile neutropenia threshold for primary G-CSF prophylaxis in breast cancer?

Tallal Younis - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Filgrastim

Measuring treatment-induced peripheral neuropathy in patients with cancer.

Tito R. Mendoza - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Oxaliplatin

Outpatient management of pulmonary embolism in cancer patients: A matched-cohort analysis.

Adi Joseph Klil-Drori - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Epoetin zeta in patients with hematological malignancies with or without iron supplementation: A sub-analysis of the SYNERGY study.

Isabelle Laure Ray-Coquard - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Epo-zeta

Patterns of palliative care utilization and end of life care in adult patients with cancer who died as inpatients at Mayo Clinic.

Collin Thomas Zimmerman - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts